Netherlands· NL-d9b5e6663853
Clomifeencitraat Eureco-Pharma 50 mg, tabletten
A clomifene product containing clomifeendiwaterstofcitraat, registered in Netherlands by Eureco-Pharma B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Clomifene is registered in 12 of 19 countries.
Countries holding a registration under ATC G03GB02 (clomifene), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Clomifene · ATC G03GB02
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Franceprice
- Germany
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of clomifene costs, country by country.
Normalised to the WHO defined daily dose (9 mg), the median price runs from $0.10 in Italy to $0.76 in United States — a ×7.3 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Clomifene · price per daily dose (9 mg)
USD · FX 28 Sept 2026
- US United States$0.76 (acquisition cost)
- FR France$0.14
- IT Italy$0.10
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- CLOMIFEENDIWATERSTOFCITRAAT
- Manufacturer
- Eureco-Pharma B.V.
- Country
- Netherlands (NL)
- ATC code
- G03GB02
- ATC class
- Clomifene
- Defined daily dose
- 9 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id128578//53363
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for clomifene.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Clomifene · interactions on record
2 records
- 2 severe
Most severe, free to view
- BexaroteneL01XF03severe
- BexarotenL01XX25severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Clomifene in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4b5cda32-1fc9-42e5-92a0-152bf673cfa6 GET /v1/drugs/4b5cda32-1fc9-42e5-92a0-152bf673cfa6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h53363_smpc.pdf",
"strength": null,
"atc_label": "Clomifene",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg128578",
"excipients": [
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"MAÏSZETMEEL",
"TALK (E 553b)"
],
"substances": [
"CLOMIFEENDIWATERSTOFCITRAAT"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h128578.pdf",
"authorised_at": "2024/04/19",
"procedure_number": null,
"dispensing_status": "Uitsluitend recept",
"registration_number": "128578//53363",
"additional_monitoring": "N"
}See everything about clomifene.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.